Search
DE EN
more info

Contact:
Phone:+49 0761 1514 440 Fax:+49 0761 1514 460 Email: info@falkfoundation.org

Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 1/2026

Edition 4/2025

Edition 3/2025

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Liver and Bile

Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States

J Hepatol. 2025;83(1):21-30

Wallace C, Gamkrelidze I, Estes C, Razavi H, Sanyal AJ

Liver and Bile

Treatment options to support the elimination of hepatitis C: An open-label, factorial, randomised controlled non-inferiority trial

Lancet. 2025;405(10491):1769-1780

Cooke GS, Hung LM, Flower B, McCabe L, Hang VTK, Thu VT, Thuan DT, Dung NT, Phuong LT, Khoa DB, An NTC, Thach PN, Huong VTT, Bich DT, Tuyen NK, Ansari MA, Le Ngoc C, Quang VM, Phuong NTN, Thao LT, Tran NB, Kestelyn E, Kingsley C, Van Doorn R, Rahman M, Pett SL, Thwaites GE, Barnes E, Day JN, Chau NVV, Walker AS

Liver and Bile

Estimating the annual number of hepatitis C virus infections through vertical transmission at country, regional, and global levels: A data synthesis study

Lancet Gastroenterol Hepatol. 2025;10(10):904-914

Trickey A, Artenie A, Feld JJ, Vickerman P

Liver and Bile

The impact of hepatitis B surface antigen reduction via small interfering RNA treatment on natural and vaccine (BRII-179)-induced hepatitis B virus-specific humoral and cellular immune responses

Gastroenterology. 2025;169(1):136-149

Ji Y, Le Bert N, Lai-Hung Wong G, Douglas MW, Lee A, Zhu C, Wang B, Lv J, Li D, Tan Y, Ma H, Chen J, Chen X, Zhu Q, Yuen MF, Bertoletti A

Liver and Bile

Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis

Hepatology. 2025;82(1):127-139

With expert opinion

Hsu CL, Wang L, Maestri E, Jacob AR, Do WL, Mayo S, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS, Jr., Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Wang XW, Schnabl B; AlcHepNet Investigators

Liver and Bile

Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Lancet Gastroenterol Hepatol. 2025;10(8):734-745

Loomba R, Kowdley KV, Rodriguez J, Kim NJ, Alvarez AM, Morrow L, Jeglinski B, Clawson A, Chowdhury S, Bain G, Odrljin T

Liver and Bile

Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): Results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Lancet. 2025;406(10505):821-831

Loomba R, Morgan E, Yousefi K, Li D, Geary R, Bhanot S, Alkhouri N; ION224-CS2 Investigators

Liver and Bile

Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Lancet. 2025;406(10504):719-730

Noureddin M, Frias JP, Neff GW, Lucas KJ, Behling C, Bedossa P, Dubourg J, Chan D, Burch M, Fong E, de Temple B, Minerva M, Barrett K, Shringarpure R, Tillman EJ, Rolph T, Cheng A, Yale K

Liver and Bile

Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis

N Engl J Med. 2025;392(21):2089-2099

Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group